Sentences with phrase «duchenne drug»

PTC Therapeutics snatches up controversial Marathon Duchenne drug.

The politics of Marathan Pharma's Duchenne drug price hike are getting messy.

Marathon had free reign over its pricing thanks to the lack of available Duchenne drug competitors.

Duchenne drugs have fostered recent controversy in the U.S..

Not exact matches

Sarepta Therapeutics, which won a pioneering Food and Drug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmeDrug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmedrug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatments.

And Marathon barely did any actual clinical legwork to get the drug cleared for Duchenne — it relied on 1990 - era clinical trial data before tacking on just enough study material to win an approval that doesn't even address the root cause of the disease.

Still, the fact that 250 Duchenne patients are willing to take a chance on the drug despite insurer pushback is a positive sign for Sarepta.

The saga of Sarepta Therapeutics» rare disease drug Exondys 51, the first - ever treatment for the degenerative movement disorder Duchenne muscular dystrophy, has taken yet another turn.

When Sarepta Therapeutics nabbed a pioneering approval for a Duchenne muscular dystrophy (DMD) drug last year, it won more than just bragging rights and a controversial FDA approval: the firm also landed a coveted «priority review voucher,» which can either be sold off to another company or used to slash the review period for a future Sarepta treatment.

Here's some of what's going on in the health care world as we head into Easter weekend: payers are pushing back against PTC Therapeutcics» controversial Duchenne muscular dystropy drug; insurers are cautiously lauding new rules for Obamacare's marketplaces; a fascinating lawsuit in Arkansas explores the ethics of drug making; and a new test for Zika virus can produce results within an hour.

While Marathon asserts that its list price is reasonable for treating such a devastating condition, it's unclear whether or not insurance companies will be eager to cover the drug for Duchenne patients.

I say «curious» because Marathon came under intense scrutiny for its initial plans to hike the drug's price to $ 89,000 per year even though it's available for a mere pittance in other countries (and doesn't actually address the root causes of Duchenne, but rather just some of its muscle - wasting symptoms).

PTCT, +3.33 % plans to buy privately - held Marathon Pharmaceuticals» controversial Duchenne muscular dystrophy drug for about $ 75 million in cash and $ 65 million in PTC common stock.

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) gained more than 13 percent Friday after the FDA found that the company's experimental drug to treat Duchenne muscular dystrophy may work.

A study published by scientists at University of Massachusetts Medical School and the University of Alabama at Birmingham provides insight into the mechanism of action of the drug ataluren, which is showing promise in treating Duchenne muscular dystrophy and cystic fibrosis.

Laboratory fruit flies are used for quick screening of candidate drug treatments for Duchenne muscular dystrophy.

Oligonucleotide treatments recently have been approved by the Food and Drug Administration for two neuromuscular diseases: Duchenne's muscular dystrophy and spinal muscular atrophy (SMA).

They found the same drug will also switch off similar signals in a protein implicated in Duchenne Muscular Dystrophy (DMD).

UPDATE 9/9/16: The SRPT stock jumped in price to over $ 53 a share today (9/19/16) on the news that Sarepta's drug, Exondys 51, which treats Duchenne muscular dystrophy has been given accelerated approval.